BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 33872660)

  • 1. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
    Ramaiah MJ; Tangutur AD; Manyam RR
    Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of histone deacetylases (HDACs) in human cancer.
    Ropero S; Esteller M
    Mol Oncol; 2007 Jun; 1(1):19-25. PubMed ID: 19383284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
    Hutt DM; Roth DM; Marchal C; Bouchecareilh M
    Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone acetylation and the cell-cycle in cancer.
    Wang C; Fu M; Mani S; Wadler S; Senderowicz AM; Pestell RG
    Front Biosci; 2001 Apr; 6():D610-29. PubMed ID: 11282573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review.
    Vahid F; Zand H; Nosrat-Mirshekarlou E; Najafi R; Hekmatdoost A
    Gene; 2015 May; 562(1):8-15. PubMed ID: 25701602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer.
    Mekala JR; Naushad SM; Ponnusamy L; Arivazhagan G; Sakthiprasad V; Pal-Bhadra M
    Gene; 2018 Jan; 641():248-258. PubMed ID: 29038000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
    Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
    Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone acetylation in gene regulation.
    Verdone L; Agricola E; Caserta M; Di Mauro E
    Brief Funct Genomic Proteomic; 2006 Sep; 5(3):209-21. PubMed ID: 16877467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors: current status and overview of recent clinical trials.
    Ma X; Ezzeldin HH; Diasio RB
    Drugs; 2009 Oct; 69(14):1911-34. PubMed ID: 19747008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
    Hanikoglu A; Hanikoglu F; Ozben T
    Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone acetyl transferases as emerging drug targets.
    Dekker FJ; Haisma HJ
    Drug Discov Today; 2009 Oct; 14(19-20):942-8. PubMed ID: 19577000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC modulation and cell death in the clinic.
    Dell'Aversana C; Lepore I; Altucci L
    Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDACi--going through the mechanisms.
    Wanczyk M; Roszczenko K; Marcinkiewicz K; Bojarczuk K; Kowara M; Winiarska M
    Front Biosci (Landmark Ed); 2011 Jan; 16(1):340-59. PubMed ID: 21196174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia.
    Roccaro AM; Sacco A; Jia X; Azab AK; Maiso P; Ngo HT; Azab F; Runnels J; Quang P; Ghobrial IM
    Blood; 2010 Sep; 116(9):1506-14. PubMed ID: 20519629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC inhibition promotes neuronal outgrowth and counteracts growth cone collapse through CBP/p300 and P/CAF-dependent p53 acetylation.
    Gaub P; Tedeschi A; Puttagunta R; Nguyen T; Schmandke A; Di Giovanni S
    Cell Death Differ; 2010 Sep; 17(9):1392-408. PubMed ID: 20094059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics.
    Hadnagy A; Beaulieu R; Balicki D
    Mol Cancer Ther; 2008 Apr; 7(4):740-8. PubMed ID: 18413789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylation of proteins as novel target for antitumor therapy: review article.
    Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
    Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.